2
|
Varsha V, Radhika S, Anilkumar G. An Overview of Julia-lythgoe Olefination. Curr Org Synth 2024; 21:97-126. [PMID: 37218208 DOI: 10.2174/1570179420666230510104114] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2022] [Revised: 02/03/2023] [Accepted: 02/13/2023] [Indexed: 05/24/2023]
Abstract
Julia-Lythgoe olefination (or simply Julia olefination) is an olefination process between phenyl sulfones and aldehydes (or ketones) to give alkenes after alcohol functionalization and reductive elimination using sodium amalgam or SmI2. It is mainly used to synthesize E-alkenes and is a key step in numerous total syntheses of many natural products. This review exclusively deals with the Julia-Lythgoe olefination and concentrates mainly on the applications of this reaction in natural product synthesis covering literature up to 2021.
Collapse
Affiliation(s)
- Vijayan Varsha
- School of Chemical Sciences, Mahatma Gandhi University, Priyadarsini Hills P.O, Kottayam, Kerala, 686560, India
| | - Sankaran Radhika
- School of Chemical Sciences, Mahatma Gandhi University, Priyadarsini Hills P.O, Kottayam, Kerala, 686560, India
| | - Gopinathan Anilkumar
- School of Chemical Sciences, Mahatma Gandhi University, Priyadarsini Hills P.O, Kottayam, Kerala, 686560, India
| |
Collapse
|
4
|
Zhu J, Sainulabdeen A, Akers K, Adi V, Sims JR, Yarsky E, Yan Y, Yu Y, Ishikawa H, Leung CK, Wollstein G, Schuman JS, Wei W, Chan KC. Oral Scutellarin Treatment Ameliorates Retinal Thinning and Visual Deficits in Experimental Glaucoma. Front Med (Lausanne) 2021; 8:681169. [PMID: 34414202 PMCID: PMC8369066 DOI: 10.3389/fmed.2021.681169] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2021] [Accepted: 07/07/2021] [Indexed: 01/29/2023] Open
Abstract
Purpose: Intraocular pressure (IOP) is currently the only modifiable risk factor for glaucoma, yet glaucoma can continue to progress despite controlled IOP. Thus, development of glaucoma neurotherapeutics remains an unmet need. Scutellarin is a flavonoid that can exert neuroprotective effects in the eye and brain. Here, we investigated the neurobehavioral effects of scutellarin treatment in a chronic IOP elevation model. Methods: Ten adult C57BL/6J mice were unilaterally injected with an optically clear hydrogel into the anterior chamber to obstruct aqueous outflow and induce chronic IOP elevation. Eight other mice received unilateral intracameral injection of phosphate-buffered saline only. Another eight mice with hydrogel-induced unilateral chronic IOP elevation also received daily oral gavage of 300 mg/kg scutellarin. Tonometry, optical coherence tomography, and optokinetics were performed longitudinally for 4 weeks to monitor the IOP, retinal nerve fiber layer thickness, total retinal thickness, visual acuity, and contrast sensitivity of both eyes in all three groups. Results: Intracameral hydrogel injection resulted in unilateral chronic IOP elevation with no significant inter-eye IOP difference between scutellarin treatment and untreated groups. Upon scutellarin treatment, the hydrogel-injected eyes showed less retinal thinning and reduced visual behavioral deficits when compared to the untreated, hydrogel-injected eyes. No significant difference in retinal thickness or optokinetic measures was found in the contralateral, non-treated eyes over time or between all groups. Conclusion: Using the non-invasive measuring platform, oral scutellarin treatment appeared to preserve retinal structure and visual function upon chronic IOP elevation in mice. Scutellarin may be a novel neurotherapeutic agent for glaucoma treatment.
Collapse
Affiliation(s)
- Jingyuan Zhu
- Beijing Tongren Eye Center, Beijing Key Laboratory of Intraocular Tumor Diagnosis and Treatment, Beijing Ophthalmology & Visual Sciences Key Lab, Medical Artificial Intelligence Research and Verification Key Laboratory of the Ministry of Industry and Information Technology, Beijing Tongren Hospital, Capital Medical University, Beijing, China,Department of Ophthalmology, NYU Grossman School of Medicine, NYU Langone Health, New York University, New York, NY, United States
| | - Anoop Sainulabdeen
- Department of Ophthalmology, NYU Grossman School of Medicine, NYU Langone Health, New York University, New York, NY, United States,Department of Surgery and Radiology, College of Veterinary and Animal Sciences, Kerala Veterinary and Animal Sciences University, Thrissur, India
| | - Krystal Akers
- Department of Ophthalmology, NYU Grossman School of Medicine, NYU Langone Health, New York University, New York, NY, United States
| | - Vishnu Adi
- Department of Ophthalmology, NYU Grossman School of Medicine, NYU Langone Health, New York University, New York, NY, United States
| | - Jeffrey R. Sims
- Department of Ophthalmology, NYU Grossman School of Medicine, NYU Langone Health, New York University, New York, NY, United States
| | - Eva Yarsky
- Department of Ophthalmology, NYU Grossman School of Medicine, NYU Langone Health, New York University, New York, NY, United States
| | - Yi Yan
- Department of Ophthalmology, NYU Grossman School of Medicine, NYU Langone Health, New York University, New York, NY, United States
| | - Yu Yu
- Pleryon Therapeutics Limited, Shenzhen, China
| | - Hiroshi Ishikawa
- Department of Ophthalmology, NYU Grossman School of Medicine, NYU Langone Health, New York University, New York, NY, United States,Department of Biomedical Engineering, Tandon School of Engineering, New York University, New York, NY, United States
| | - Christopher K. Leung
- Hong Kong Eye Hospital, University Eye Center, Hong Kong, China,Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong, China,Department of Ophthalmology, The University of Hong Kong, Hong Kong, China
| | - Gadi Wollstein
- Department of Ophthalmology, NYU Grossman School of Medicine, NYU Langone Health, New York University, New York, NY, United States,Department of Biomedical Engineering, Tandon School of Engineering, New York University, New York, NY, United States
| | - Joel S. Schuman
- Department of Ophthalmology, NYU Grossman School of Medicine, NYU Langone Health, New York University, New York, NY, United States,Department of Biomedical Engineering, Tandon School of Engineering, New York University, New York, NY, United States,Center for Neural Science, College of Arts and Science, New York University, New York, NY, United States,Neuroscience Institute, NYU Grossman School of Medicine, NYU Langone Health, New York University, New York, NY, United States
| | - Wenbin Wei
- Beijing Tongren Eye Center, Beijing Key Laboratory of Intraocular Tumor Diagnosis and Treatment, Beijing Ophthalmology & Visual Sciences Key Lab, Medical Artificial Intelligence Research and Verification Key Laboratory of the Ministry of Industry and Information Technology, Beijing Tongren Hospital, Capital Medical University, Beijing, China,Wenbin Wei
| | - Kevin C. Chan
- Department of Ophthalmology, NYU Grossman School of Medicine, NYU Langone Health, New York University, New York, NY, United States,Department of Biomedical Engineering, Tandon School of Engineering, New York University, New York, NY, United States,Center for Neural Science, College of Arts and Science, New York University, New York, NY, United States,Neuroscience Institute, NYU Grossman School of Medicine, NYU Langone Health, New York University, New York, NY, United States,Department of Radiology, NYU Grossman School of Medicine, NYU Langone Health, New York University, New York, NY, United States,*Correspondence: Kevin C. Chan
| |
Collapse
|
5
|
Shokoohimand A, Arfaee F, Asghari A, Khaksar E. Effects of topical administration of tafluprost and combination of tafluprost and timolol or tafluprost and betaxolol on Schirmer tear test, intraocular pressure, and pupil size in clinically healthy dogs. Int Ophthalmol 2020; 40:2585-2592. [PMID: 32504308 DOI: 10.1007/s10792-020-01439-9] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2019] [Accepted: 05/22/2020] [Indexed: 11/25/2022]
Abstract
PURPOSE The aim of this study was to evaluate the effects of 0.0015% preservative-free (PF) tafluprost alone and in combination with 0.5% timolol maleate or 0.5% betaxolol HCl on Schirmer tear test (STT), intraocular pressure (IOP), and pupil diameter (PD) in clinically normal dogs. METHODS Twenty-one healthy adult castrated male cross-bred dogs were used in this study. Dogs were randomly divided into three groups. The first group received one drop of (PF) tafluprost (Taf), in a randomly selected eye. The second group received one drop of (PF) tafluprost plus one drop of timolol maleate (Taf-Tim), and the last group received one drop of (PF) tafluprost plus one drop of betaxolol HCl, (Taf-Bet). In all groups, the fellow eyes were served as control and received one drop of saline as a placebo. IOP, STT, and PD measurements were performed at the baseline and every 30 min for the first 2 h, every 2 h for the next 10 h, and at 24 h and 36 h post-instillation (PI). RESULTS In all groups, significant differences in IOP values were observed between treated and untreated eyes (Taf: p < 0.001, Taf-Tim: p = 0.014, Taf-Bet: p = 0.008). The maximum reduction in mean IOP after unilateral administration of Taf, Taf-Tim, and Taf-Bet was 8.3 mmHg, 10.7 mmHg, and 13 mmHg, respectively. No significant differences in STT values were observed between treated and untreated eyes at any time points. In all groups, significant differences in PD values were observed between treated and untreated eyes in all time points except the baseline and 36 h post-drug instillation (p < 0.001). CONCLUSIONS Tafluprost alone or in combination with timolol and betaxolol was able to reduce intraocular pressure. The greatest effect of the drugs occurred 6 and 8 h PI. The present study revealed that the combination of tafluprost/betaxolol is more potent in decreasing IOP than tafluprost alone or a combination of tafluprost/timolol in healthy dogs.
Collapse
Affiliation(s)
- Armin Shokoohimand
- Department of Clinical Science, Faculty of Specialized Veterinary Sciences, Science and Research Branch, Islamic Azad University, Hesarak, Tehran, 1477893855, Islamic Republic of Iran
| | - Farnoosh Arfaee
- Department of Clinical Science, Faculty of Specialized Veterinary Sciences, Science and Research Branch, Islamic Azad University, Hesarak, Tehran, 1477893855, Islamic Republic of Iran.
| | - Ahmad Asghari
- Department of Clinical Science, Faculty of Specialized Veterinary Sciences, Science and Research Branch, Islamic Azad University, Hesarak, Tehran, 1477893855, Islamic Republic of Iran
| | - Ehsan Khaksar
- Department of Clinical Science, Faculty of Veterinary Sciences, Garmsar Branch, Islamic Azad University, Garmsar, 3581631167, Islamic Republic of Iran
| |
Collapse
|
6
|
Esaki Y, Katsuta O, Kamio H, Noto T, Mano H, Iwamura R, Yoneda K, Odani-Kawabata N, Morishima K, Shams NK. The Antiglaucoma Agent and EP2 Receptor Agonist Omidenepag Does Not Affect Eyelash Growth in Mice. J Ocul Pharmacol Ther 2020; 36:529-533. [PMID: 32412835 PMCID: PMC7482127 DOI: 10.1089/jop.2020.0003] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
Purpose: The present study investigated the effects of the antiglaucoma agent and selective E2 receptor agonist omidenepag isopropyl (OMDI) on eyelash growth in comparison with a prostaglandin analog (prostamide receptor agonist) in mice. Methods: Four-week-old female mice (C57BL/6J) were divided into 3 groups of n = 10 each. The groups were administered 3 μL of 0.003% OMDI solution, the vehicle (negative control), or a 0.03% bimatoprost solution (positive control) on the upper eyelids of the right eyes once daily for 14 days. On the 15th day, all animals were euthanized, and the upper eyelids with eyelashes were fixed with 10% neutral formalin. Eyelashes were evaluated for number, length, and thickness using a stereomicroscope. Specimens were then paraffin-embedded and stained with hematoxylin and eosin, followed by microscopic examination to assess eyelash morphology and growth cycle. Results: Eyelash number (143.5 ± 6.7/eyelid), thickness, and percentage of dermal papilla in the anagen phase in the OMDI group were similar to those observed in the vehicle group (eyelash number, 144.2 ± 5.7/eyelid). In contrast, eyelash number (166.7 ± 7.0/eyelid), thickness, and the percentage of dermal papilla in the anagen phase were significantly greater in the bimatoprost group compared with those of the vehicle group. Conclusions: Unlike existing prostaglandin analogs, our findings indicate that OMDI has no effect on eyelash growth in mice, suggesting that it may be a promising antiglaucoma agent with a reduced number of adverse effects.
Collapse
Affiliation(s)
- Yoshihiko Esaki
- Santen Pharmaceutical Co., Ltd., Research and Development Division, Nara, Japan
| | - Osamu Katsuta
- Santen Pharmaceutical Co., Ltd., Research and Development Division, Nara, Japan
| | - Hitomi Kamio
- Santen Pharmaceutical Co., Ltd., Research and Development Division, Nara, Japan
| | - Takahisa Noto
- Santen Pharmaceutical Co., Ltd., Research and Development Division, Nara, Japan
| | - Hidetoshi Mano
- Santen Pharmaceutical Co., Ltd., Research and Development Division, Nara, Japan
| | - Ryo Iwamura
- Ube Industries, Ltd., Pharmaceuticals Research Laboratory, Pharmaceutical Division, Yamaguchi, Japan
| | - Kenji Yoneda
- Ube Industries, Ltd., Pharmaceuticals Research Laboratory, Pharmaceutical Division, Yamaguchi, Japan
| | - Noriko Odani-Kawabata
- Santen Pharmaceutical Co., Ltd., Osaka, Japan.,Santen, Inc., Research and Development Division, Emeryville, California, USA
| | - Kenji Morishima
- Santen Pharmaceutical Co., Ltd., Research and Development Division, Nara, Japan
| | - Naveed K Shams
- Santen, Inc., Research and Development Division, Emeryville, California, USA
| |
Collapse
|